Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. by Strazzabosco M et al.
Osteopontin: a new player in
regulating hepatic ductular reaction
and hepatic progenitor cell responses
during chronic liver injury
Mario Strazzabosco,1,2 Luca Fabris,2,3 Emanuele Albano4
In recent years, an increasing number of
reports have shown the involvement of
osteopontin (OPN), a pleiotropic cytokine
and an important component of the extra-
cellular matrix (ECM), in the pathogen-
esis of liver injury and the development of
fibrosis.1 2 OPN is also frequently overex-
pressed in hepatocellular carcinoma
(HCC), where it modulates HCC growth,
invasion and metastasis,2 and in cholangio-
carcinoma, where its expression bears
prognostic significance. Previous studies3
have shown that in injured livers OPN is
expressed by hepatic stellate cells (HSC)
and upregulates collagen I production.
Interestingly, in HSC, OPN expression
appears to be downstream of SOX9, a
Hedgehog- and Notch-controlled tran-
scription factor that is expressed also in
biliary cells and hepatic progenitor cells
(HPC)/hepatocytes committed to the
biliary fate.4–6 In this issue of Gut, two
papers investigate the role of OPN in
HPC-driven ductular reaction (DR) in rela-
tion to the progression of liver fibrosis.7 8
DR, a histological lesion present in
most chronic liver diseases, is a dynamic,
multicellular complex characterised by the
presence of ‘reactive’ ductular epithelial
cells, arranged in irregular strings along
the margins of the portal tract in close
contact with mesenchymal, inflammatory
and endothelial cells. Reactive ductular
cells acquire novel functions including the
secretion of cytokines, chemokines, growth
factors and angiogenic factors, enabling
them to establish intense paracrine commu-
nications with a variety of cells and to
orchestrate the repair of the epithelial
wound. DR cells acquire also limited mes-
enchymal properties that endow them with
increased motility and the ability to detach
from the epithelial layer. Ductular reaction
is driven by the activation of the HPC com-
partment, a compensatory mechanism of
liver repair triggered when proliferative
ability of mature hepatocytes or cholangio-
cytes is compromised9 such as in most
human liver diseases.
Several studies indicate that the extent
of DR closely correlates with the amount
of collagen deposition, ultimately leading
to tissue scarring and lobular architectural
distortion.10 This process depends upon a
complex interplay between paracrine
signals released by HPC/DR able to acti-
vate a fibrogenic programme and promote
changes in the ECM.10 In this context,
OPN is a molecule of particular interest,
being able to act as an ECM protein direct-
ing cell motility and adhesion as well as a
cytokine regulating T-lymphocyte and
macrophage responses in inflammation.1
The two studies published in this issue of
Gut further expand the role of OPN in
HPC activation and DR as a critical mech-
anism responsible for the progression of
liver fibrosis across different experimental
models of chronic liver injury.7 8
In particular, the two papers show that
OPN produced by HPC contributes to DR
by stimulating HPC proliferation and
migration, while concomitantly it reduces
hepatocyte proliferative capability.7 8
Furthermore, they demonstrate that OPN
plays an important role in regulating the
interaction between HPC and HSC, and in
modulating myofibroblast activation and
collagen production synergistically with
transforming growth factor-β (TGF-β).7 8
In turn, TGF-β influences OPN signalling
in cultured HPC cell lines.7 In line with
these observations, OPN deficiency or
OPN inactivation with OPN-specific apta-
mers or neutralising antibodies reduces
DR, HPC response and fibrogenesis in dif-
ferent experimental models of chronic
liver disease (figure 1). Altogether, the two
studies nicely complement each other in
addressing the importance of OPN in
driving HPC expansion and DR.
Although these two reports make an
important contribution in elucidating the
complex role of OPN in chronic liver dis-
eases, a number of issues remain unsolved.
Two forms of OPN are known: an intra-
cellular form (iOPN) involved in regulat-
ing cell migration and inflammatory
signalling in lymphocytes and dendritic
cells, and a secreted form (sOPN) with
cytokine and ECM protein properties.1
The data of Coombes et al8 using
OPN-specific aptamers or neutralising
antibodies suggest that sOPN has an
important role in fibrogenesis. However,
further studies are required to fully under-
stand the role of iOPN. The second ques-
tion that remains lingering is the cellular
origin of OPN in liver diseases. Several
cells, including hepatocytes, macrophages,
cholangiocytes, T-lymphocytes, natural
killer T-cells and HSC, contribute to
hepatic OPN production,2 making it diffi-
cult to dissect the specific contribution of
each cell type to the overall effects. Using
immunohistochemistry and morphometry,
Wang and coworkers7 studied the relative
contribution of different hepatic cell
populations to OPN production in
control and thioacetamide (TAA)-treated
mice. They show that, while in control
mice hepatocytes and cholangiocytes are
the main sources of OPN in injured livers,
HPC and HSC appreciably contribute to
OPN production.7 However, even in
these conditions more than 90% of OPN
staining involves hepatocytes.7 Further
studies using animals with selective inacti-
vation of the OPN gene in specific hepatic
cell populations are required to better
elucidate the origin of OPN that drives
DR. Finally, a third question involves the
difficulty in discriminating among the
pleiotropic actions of OPN. It remains
unclear to what extent the capacity of
OPN to stimulate HPC response and
fibrogenesis depends on its activity as a
pro-inflammatory cytokine or by its
ability to stimulate HSC activation and
collagen production.2 3 Dissecting the
pro-inflammatory activity of OPN is
important in characterising its role in DR
as this response implies a significant con-
tribution of inflammatory cells.9
Altogether, the results presented by
Wang et al7 and Coombes et al8 along
with previous data suggest OPN as a
possible therapeutic target for liver
fibrosis. Furthermore, the results of the
inhibition studies in these manuscripts
represent a further strong piece of evi-
dence that the ‘Holy Grail’ of chronic
liver disease progression lies buried in
the crosstalk between epithelial and mes-
enchymal/inflammatory cells,10 11 and
whoever follows just one lead will never
find it.
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Figure 1 Osteopontin (OPN) is an important regulator of the interaction between ductular reaction (DR) cells and hepatic stellate cells (HSC): it
may represent a molecular target for therapeutic interference. Following chronic liver injury, OPN produced by DR cells, including hepatic progenitor
cell (HPC), stimulates HSC recruitment and activation into myofibroblasts, where it induces transforming growth factor-β signalling and increased
collagen deposition; on the parenchymal side, OPN simulates HPC proliferation and migration, while concomitantly downregulating hepatocyte
proliferation (green arrow). OPN blockade by specific aptamers or neutralising antibodies halts the crosstalk between DR cells and HSC, thereby
hampering myofibroblast activation and reducing matrix production, while turning up hepatocyte proliferation (red arrow).
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